New drug ESG406 enters human testing for Hard-to-Treat cancers

NCT ID NCT06979674

Recruiting now Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 32 times

Summary

This early-phase study tests a new drug called ESG406 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and to see if the drug can shrink tumors. About 556 participants will take part in this open-label study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China

Contact
The First Affiliated Hospital of Xi 'An Jiaotong University
RECRUITING

Xi’an, Shanxi, 710061, China

Contact
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED/METASTATIC SOLID TUMORS